IACH News Podcasts

Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

December 3rd- Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network - PMC

CME Congresses .

December 3rd- Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network – PMC

December 1st- Prof. Florent Malard- What to expect at #ASH25 in GVHD

CME Congresses .

December 1st- Prof. Florent Malard- What to expect at #ASH25 in GVHD

November 28th- ASH 2025 Late-Breaking Preview- LBA-1: inMMyCAR Phase 1, KLN-1010 in RRMM

CME Congresses .

November 28th- ASH 2025 Late-Breaking Preview- LBA-1: inMMyCAR Phase 1, KLN-1010 in RRMM

November 27th- Optimizing the Use of Melflufen in Relapsed/Refractory Multiple Myeloma

CME Congresses .

November 27th- Optimizing the Use of Melflufen in Relapsed/Refractory Multiple Myeloma

November 25th- Prof. Mohamad Mohty- Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

CME Congresses .

November 25th- Prof. Mohamad Mohty- Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

November 25th- Prof. Mohamad Mohty- What to Expect at #ASH25 in Multiple Myeloma

CME Congresses .

November 25th- Prof. Mohamad Mohty- What to Expect at #ASH25 in Multiple Myeloma

November 13th- Dr. Jan Burger- Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL and SLL

CME Congresses .

November 13th- Dr. Jan Burger- Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL and SLL

September 26th- Prof. Mohamad Mohty- Immunostimulatory CELMoD combination overcomes resistance to T cell engagers caused by high multiple myeloma burden

CME Congresses .

September 26th- Prof. Mohamad Mohty- Immunostimulatory CELMoD combination overcomes resistance to T cell engagers caused by high multiple myeloma burden

September 24th- Prof. Robert Wynn- Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation

CME Congresses .

September 24th- Prof. Robert Wynn- Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation

September 19th- Prof. Samir Parekh- Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy

CME Congresses .

September 19th- Prof. Samir Parekh- Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy